{
    "clinical_study": {
        "@rank": "52078", 
        "arm_group": [
            {
                "arm_group_label": "Placebo", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Placebo Comparator"
            }, 
            {
                "arm_group_label": "MEDI9929 - Low Dose", 
                "arm_group_type": "Experimental", 
                "description": "MEDI9929 (Investigational Product)"
            }, 
            {
                "arm_group_label": "MEDI9929 - Medium Dose", 
                "arm_group_type": "Experimental", 
                "description": "MEDI9929 (Investigational Product)"
            }, 
            {
                "arm_group_label": "MEDI9929 - High Dose", 
                "arm_group_type": "Experimental", 
                "description": "MEDI9929 (Investigational Product)"
            }
        ], 
        "brief_summary": {
            "textblock": "The primary objective of the study is to evaluate the effect of 3 dose levels of MEDI9929\n      (AMG 157) on asthma exacerbations in adult subjects with inadequately controlled, severe\n      asthma."
        }, 
        "brief_title": "Study to Evaluate the Efficacy and Safety of MEDI9929 (AMG 157) in Adult Subjects With Inadequately Controlled, Severe Asthma", 
        "completion_date": {
            "#text": "December 2016", 
            "@type": "Anticipated"
        }, 
        "condition": "Asthma", 
        "condition_browse": {
            "mesh_term": "Asthma"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Age 18 through 75\n\n          -  BMI between 18-40 kg/m2 and weight greater than or equal 40 kg\n\n          -  Documented physician-diagnosed asthma  - Subjects must have received a\n             physician-prescribed asthma controller regimen with medium- or high-dose ICS plus\n             LABA -If on asthma controller medications in addition to ICS plus LABA, the dose of\n             the other asthma controller medications (leukotriene receptor inhibitors,\n             theophylline, secondary ICS, LAMA, cromones, or maintenance oral prednisone or\n             equivalent up to a maximum of 10 mg daily or 20 mg every other day for the\n             maintenance treatment of asthma) must be stable. -Subjects must have a documented\n             history of at least 2 asthma exacerbation events.\n\n        Exclusion Criteria:\n\n          -  Diagnosis of vocal cord dysfunction, reactive airways dysfunction syndrome,\n             hyperventilation and panic attacks, or other mimics of asthma.\n\n          -  Current smokers or subjects with a smoking history of \u2265 10 pack years\n\n          -  Former smokers with < 10 pack years must have stopped for at least 1 year to be\n             eligible.\n\n          -  Any concomitant respiratory disease that in the opinion of the investigator and/or\n             medical monitor will interfere with the evaluation of the investigational product or\n             interpretation of subject safety or study results (eg, chronic obstructive pulmonary\n             disease, cystic fibrosis, pulmonary fibrosis, bronchiectasis, allergic\n             bronchopulmonary aspergillosis, Churg-Strauss syndrome).\n\n          -  Evidence of active liver disease.\n\n          -  History of Cancer, except for basal cell carcinoma or insitu carcinoma of the cervix\n             treated with apparent success with curative therapy or other malignancies are\n             eligible provided that curative therapy was completed -Known history of active\n             tuberculosis (TB)\n\n          -  History of anaphylaxis to any biologic therapy\n\n          -  Positive medical history for hepatitis B or C\n\n          -  Subject with HIV or subject taking antiretroviral medications, as determined by\n             medical history and/or subject's verbal report."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "75 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "1383", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "December 4, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02054130", 
            "org_study_id": "CD-RI-MEDI9929-1146", 
            "secondary_id": "2013-003269-33"
        }, 
        "intervention": [
            {
                "arm_group_label": "Placebo", 
                "description": "Placebo", 
                "intervention_name": "Placebo", 
                "intervention_type": "Drug", 
                "other_name": "Subcutaneous repeating dose"
            }, 
            {
                "arm_group_label": "MEDI9929 - Low Dose", 
                "description": "Subcutaneous repeating dose", 
                "intervention_name": "MEDI9929 - Low Dose IP", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "MEDI9929 - Medium Dose", 
                "description": "Subcutaneous repeating dose", 
                "intervention_name": "MEDI9929 - Medium Dose IP", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "MEDI9929 - High Dose", 
                "description": "Subcutaneous repeating dose", 
                "intervention_name": "MEDI9929 - High Dose IP", 
                "intervention_type": "Drug"
            }
        ], 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": "Asthma", 
        "lastchanged_date": "May 13, 2014", 
        "link": [
            {
                "description": "Click here and search for drug information provided by the FDA", 
                "url": "http://www.fda.gov/cder/DrugSafety/DrugIndex.htm"
            }, 
            {
                "description": "Click here and search for information on any recalls, market or product safety alerts by the FDA which might have occurred with this product.", 
                "url": "http://www.fda.gov/medwatch/safety.htm"
            }
        ], 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Los Angeles", 
                        "country": "United States", 
                        "state": "California"
                    }, 
                    "name": "Research Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Miami", 
                        "country": "United States", 
                        "state": "Florida"
                    }, 
                    "name": "Research Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Miami", 
                        "country": "United States", 
                        "state": "Florida"
                    }, 
                    "name": "Research Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Oviedo", 
                        "country": "United States", 
                        "state": "Florida"
                    }, 
                    "name": "Research Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Charlotte", 
                        "country": "United States", 
                        "state": "North Carolina"
                    }, 
                    "name": "Research Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Winston-Salem", 
                        "country": "United States", 
                        "state": "North Carolina"
                    }, 
                    "name": "Research Site"
                }, 
                "status": "Withdrawn"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Dublin", 
                        "country": "United States", 
                        "state": "Ohio"
                    }, 
                    "name": "Research Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Altoona", 
                        "country": "United States", 
                        "state": "Pennsylvania"
                    }, 
                    "name": "Research Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Rock Hill", 
                        "country": "United States", 
                        "state": "South Carolina"
                    }, 
                    "name": "Research Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Spartanburg", 
                        "country": "United States", 
                        "state": "South Carolina"
                    }, 
                    "name": "Research Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Herrico", 
                        "country": "United States", 
                        "state": "Virginia"
                    }, 
                    "name": "Research Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Budapest", 
                        "country": "Hungary"
                    }, 
                    "name": "Research Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Debrecen", 
                        "country": "Hungary"
                    }, 
                    "name": "Research Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "G\u00f6d\u00f6ll\u0151", 
                        "country": "Hungary"
                    }, 
                    "name": "Research Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Komarom", 
                        "country": "Hungary"
                    }, 
                    "name": "Research Site"
                }, 
                "status": "Not yet recruiting"
            }
        ], 
        "location_countries": {
            "country": [
                "United States", 
                "Hungary"
            ]
        }, 
        "number_of_arms": "4", 
        "official_title": "A Phase 2 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of MEDI9929 in Adult Subjects With Inadequately Controlled, Severe Asthma", 
        "overall_contact": {
            "email": "ClinicalTrialEnquiries@Medimmune.com", 
            "last_name": "Jacqueline Mazza, MSHS, CCRA"
        }, 
        "overall_contact_backup": {
            "email": "clinicaltrialenquiries@medimmune.com", 
            "last_name": "Sarah Crouch"
        }, 
        "overall_official": {
            "affiliation": "MedImmune LLC", 
            "last_name": "Joe Parker, MD", 
            "role": "Study Director"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "October 2016", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Annualized asthma exacerbation rate (AER)", 
            "measure": "Rate of asthma exacerbations", 
            "safety_issue": "Yes", 
            "time_frame": "Week 52"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02054130"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "Measured by pre-bronchodilator FEV1 and FVC.", 
                "measure": "Change from baseline in pre-bronchodilator FEV1 and FVC", 
                "safety_issue": "No", 
                "time_frame": "Week 52"
            }, 
            {
                "description": "Measured by post-bronchodilator FEV1 and FVC.", 
                "measure": "Change from baseline in post-bronchodilator FEV1 and FVC", 
                "safety_issue": "No", 
                "time_frame": "Week 52"
            }, 
            {
                "description": "Measured by the Asthma Daily Diary (ACQ-6)", 
                "measure": "Change from baseline in overall symptom score measured by the Asthma Daily Diary (ACQ-6)", 
                "safety_issue": "No", 
                "time_frame": "Week 52"
            }, 
            {
                "description": "Annualized severe AER.", 
                "measure": "Rate of severe asthma exacerbations", 
                "safety_issue": "Yes", 
                "time_frame": "Week 52"
            }, 
            {
                "description": "Time to first asthma exacerbation/severe asthma exacerbation.", 
                "measure": "Time to first asthma exacerbation/severe asthma exacerbation", 
                "safety_issue": "Yes", 
                "time_frame": "Week 52"
            }, 
            {
                "description": "AQLQ[S] +12 and EQ-5D-5L", 
                "measure": "Change from Baseline in Asthma Quality of Life Questionnaire (AQLQ[S] +12) and European Quality of Life (EQ-5D-5L)", 
                "safety_issue": "No", 
                "time_frame": "Week 52"
            }, 
            {
                "description": "Number of Participants with treatment-emergent adverse events and treatment-emergent serious adverse events", 
                "measure": "Numper of Participants with treatment-emergent adverse events and treatment-emergent serious adverse events", 
                "safety_issue": "Yes", 
                "time_frame": "Week 0 (Day 1) - Week 64"
            }, 
            {
                "description": "Number of participants with positive antibodies to MEDI9929", 
                "measure": "Number of participants with positive antibodies to MEDI9929", 
                "safety_issue": "Yes", 
                "time_frame": "Week 0 (Day 1) - Week 64"
            }, 
            {
                "description": "Proportion of subjects with one or more asthma exacerbations/severe asthma exacerbations", 
                "measure": "Proportion of subjects with one or more asthma exacerbations/severe asthma exacerbations", 
                "safety_issue": "Yes", 
                "time_frame": "Week 52"
            }
        ], 
        "source": "MedImmune LLC", 
        "sponsors": {
            "collaborator": {
                "agency": "Amgen", 
                "agency_class": "Industry"
            }, 
            "lead_sponsor": {
                "agency": "MedImmune LLC", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "December 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}